RxDoctor Payments Data

Marcus Muehlbauer, MD

Gastroenterology · Gainesville, FLNPI 1093970121

Payments from drug & device makers

$393,482in general payments, 2019–2025

Across 255 payments — averaging $1543.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$160K
  • Janssen Research & Development, LLC$50K
  • AbbVie$40K
  • Takeda Pharmaceuticals U.S.A., Inc.$36K
  • Bristol Myers Squibb$31K
  • Roche Products Limited$27K
  • plus $49K from 11 others

What the payments were for

  • Food & beverage$1,22592%
  • Education$1138%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$393,482 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$341,990
Medicare patients
482
Services billed
11,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab25$728,220
Humira(Cf) PenAdalimumab55$651,885
RinvoqUpadacitinib17$141,207
XeljanzTofacitinib Citrate19$120,083
Mesalamine44$27,892
ViberziEluxadoline11$16,621
CholestyramineCholestyramine (With Sugar)50$5,860
Colestipol Hcl33$3,617
Azathioprine44$2,581
Omeprazole169$2,252
Budesonide DrBudesonide21$2,238
Mercaptopurine23$1,952
Ondansetron OdtOndansetron24$1,500
Mesalamine ErMesalamine11$1,431
Dicyclomine Hcl37$1,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$99$728,22025 claims
AbbVieRinvoq, Viberzi$40,263$157,82828 claims
PfizerXeljanz$63$120,08319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →